SGLT-2 inhibitors have a lower all-cause mortality rate compared with DPP-4 inhibitors and GLP-1R agonists, especially in terms of cardiovascular mortality and hospitalization for heart failure [101,102]. This evidence concerns the gene DPP4 and heart failure.